AzurRx BioPharma, Inc. - FORM 10-K - EX-23 - CONSENTS OF EXPERTS AND COUNSEL - March 30, 2020

Attached files

file filename
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - AzurRx BioPharma, Inc.ex32-1.htm
EX-31 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - AzurRx BioPharma, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - AzurRx BioPharma, Inc.ex31-1.htm
10-K - ANNUAL REPORT - AzurRx BioPharma, Inc.azrx10k_dec312019.htm
 
Exhibit 23
 
  CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (File No. 333-235768), Form S-8 (File No. 333-220781) and Form S-3 (File Nos. 333-226065, 333-231954, 333-231035 and 333-221275) of our report dated March 30, 2020, related to the consolidated financial statements of AzurRx BioPharma, Inc. as of December 31, 2019 and 2018 and for the years then ended, which appears in the Annual Report on Form 10-K of AzurRx BioPharma, Inc. for the year ended December 31, 2019. Our report on the consolidated financial statements of AzurRx BioPharma, Inc. includes an explanatory paragraph about the existence of substantial doubt concerning its ability to continue as a going concern.
 
 
 
/s/ Mazars USA LLP
New York, New York
March 30, 2020
 
 

AzurRx BioPharma, Inc. Reports